A Phase 3 Multi-Center Randomized Double-Blind Placebo-Controlled Study of Fostamatinib Disodium in the Treatment of wAIHA

  • STATUS
    Recruiting
  • participants needed
    90
  • sponsor
    Rigel Pharmaceuticals
Updated on 14 August 2022
Investigator
Huyen Tran, MD
Primary Contact
The Alfred Hospital (6.2 mi away) Contact
+125 other location

Summary

The primary objective of this study is to assess the efficacy of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).

Details
Condition Warm Antibody Autoimmune Hemolytic Anemia
Treatment Placebo, Fostamatinib disodium
Clinical Study IdentifierNCT03764618
SponsorRigel Pharmaceuticals
Last Modified on14 August 2022

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note